These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 38654513)

  • 21. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer's disease.
    Sun N; Mormino EC; Chen J; Sabuncu MR; Yeo BTT;
    Neuroimage; 2019 Nov; 201():116043. PubMed ID: 31344486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olfactory function reflects episodic memory performance and atrophy in the medial temporal lobe in individuals at risk for Alzheimer's disease.
    Papadatos Z; Phillips NA
    Neurobiol Aging; 2023 Aug; 128():33-42. PubMed ID: 37146503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer's disease in patients with mild cognitive symptoms.
    Arvidsson I; Strandberg O; Palmqvist S; Stomrud E; Cullen N; Janelidze S; Tideman P; Heyden A; Åström K; Hansson O; Mattsson-Carlgren N
    Alzheimers Res Ther; 2024 Mar; 16(1):61. PubMed ID: 38504336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
    Sintini I; Graff-Radford J; Senjem ML; Schwarz CG; Machulda MM; Martin PR; Jones DT; Boeve BF; Knopman DS; Kantarci K; Petersen RC; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    Brain; 2020 Jul; 143(7):2281-2294. PubMed ID: 32572464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
    Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Responsiveness of magnetic resonance imaging and neuropsychological assessment in memory clinic patients.
    Schmand B; Rienstra A; Tamminga H; Richard E; van Gool WA; Caan MW; Majoie CB
    J Alzheimers Dis; 2014; 40(2):409-18. PubMed ID: 24473187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia.
    Kim HJ; Lee JH; Cheong EN; Chung SE; Jo S; Shim WH; Hong YJ
    Curr Alzheimer Res; 2020; 17(10):893-903. PubMed ID: 33256581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.
    Ossenkoppele R; Pijnenburg YA; Perry DC; Cohn-Sheehy BI; Scheltens NM; Vogel JW; Kramer JH; van der Vlies AE; La Joie R; Rosen HJ; van der Flier WM; Grinberg LT; Rozemuller AJ; Huang EJ; van Berckel BN; Miller BL; Barkhof F; Jagust WJ; Scheltens P; Seeley WW; Rabinovici GD
    Brain; 2015 Sep; 138(Pt 9):2732-49. PubMed ID: 26141491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semantic memory activation in amnestic mild cognitive impairment.
    Woodard JL; Seidenberg M; Nielson KA; Antuono P; Guidotti L; Durgerian S; Zhang Q; Lancaster M; Hantke N; Butts A; Rao SM
    Brain; 2009 Aug; 132(Pt 8):2068-78. PubMed ID: 19515831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modifying the minimum criteria for diagnosing amnestic MCI to improve prediction of brain atrophy and progression to Alzheimer's disease.
    Vuoksimaa E; McEvoy LK; Holland D; Franz CE; Kremen WS;
    Brain Imaging Behav; 2020 Jun; 14(3):787-796. PubMed ID: 30511118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detecting biological heterogeneity patterns in ADNI amnestic mild cognitive impairment based on volumetric MRI.
    Ezzati A; Zammit AR; Habeck C; Hall CB; Lipton RB;
    Brain Imaging Behav; 2020 Oct; 14(5):1792-1804. PubMed ID: 31104279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications.
    Ferreira D; Verhagen C; Hernández-Cabrera JA; Cavallin L; Guo CJ; Ekman U; Muehlboeck JS; Simmons A; Barroso J; Wahlund LO; Westman E
    Sci Rep; 2017 Apr; 7():46263. PubMed ID: 28417965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of brain atrophy subtypes categorization in memory clinics.
    Planche V; Bouteloup V; Mangin JF; Dubois B; Delrieu J; Pasquier F; Blanc F; Paquet C; Hanon O; Gabelle A; Ceccaldi M; Annweiler C; Krolak-Salmon P; Habert MO; Fischer C; Chupin M; Béjot Y; Godefroy O; Wallon D; Sauvée M; Bourdel-Marchasson I; Jalenques I; Tison F; Chêne G; Dufouil C;
    Alzheimers Dement; 2021 Apr; 17(4):641-652. PubMed ID: 33325121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A robust brain signature region approach for episodic memory performance in older adults.
    Fletcher E; Gavett B; Crane P; Soldan A; Hohman T; Farias S; Widaman K; Groot C; Renteria MA; Zahodne L; DeCarli C; Mungas D;
    Brain; 2021 May; 144(4):1089-1102. PubMed ID: 33895818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study.
    Cumplido-Mayoral I; Brugulat-Serrat A; Sánchez-Benavides G; González-Escalante A; Anastasi F; Milà-Alomà M; López-Martos D; Akinci M; Falcón C; Shekari M; Cacciaglia R; Arenaza-Urquijo EM; Minguillón C; Fauria K; Molinuevo JL; Suárez-Calvet M; Grau-Rivera O; Vilaplana V; Gispert JD;
    Lancet Healthy Longev; 2024 Apr; 5(4):e276-e286. PubMed ID: 38555920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.